Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chinese President Pledges China Will Not Discriminate Against U.S. Businesses; Broad Healthcare Partnership Unveiled

This article was originally published in The Pink Sheet Daily

Executive Summary

The public-private partnership includes Pfizer, Johnson & Johnson, Abbott, Medtronic, General Electric, Chindex and Microsoft.

You may also be interested in...



Long-term Backer Of Stronger Trade Ties With China, U.S. Senator Warns Of Potential Economic Face-off

BEIJING - With the American economy still reeling from debilitating unemployment levels and a burgeoning international trade deficit, U.S. Senator Max Baucus (D-Mont.) jetted into Beijing this week in an attempt to resolve a series of economic disputes with China; talks with Chinese leaders could trigger changes that affect virtually every sector, including healthcare

Barack Obama's Meeting With Chinese President Bodes Well For Pan-Pacific Pharma Partnerships, Says Analyst During Shanghai Conference

SHANGHAI - Despite the financial maelstrom that has lashed economies from the Americas to Asia, U.S. President Barack Obama's April 1 meeting with Chinese President Hu Jintao is ultimately likely to boost the pharmaceutical sector in each country and the potential for pan-Pacific partnerships, according to the chief executive officer of the San Diego-based consulting firm BioForesight

Import Safety Agreement Further Entwines FDA/China Regulatory Process

Chinese manufacturers of certain drugs or active pharmaceutical ingredients selected by FDA will have to meet new registration standards as part of a memorandum of understanding signed Dec. 11 in Beijing by HHS, FDA and China's State Food and Drug Administration

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071726

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel